Aptose Biosciences (NASDAQ:APTO) Earns Hold Rating from Analysts at StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a report issued on Friday. The firm set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright decreased their price target on Aptose Biosciences from $7.00 to $2.00 and set a “buy” rating on the stock in a research note on Wednesday, November 20th.

Aptose Biosciences Price Performance

Shares of APTO opened at $0.18 on Friday. Aptose Biosciences has a 12 month low of $0.13 and a 12 month high of $2.91. The stock has a market cap of $3.26 million, a price-to-earnings ratio of -0.06 and a beta of 1.26. The company has a 50-day moving average price of $0.35 and a two-hundred day moving average price of $0.57.

Institutional Trading of Aptose Biosciences

A hedge fund recently raised its stake in Aptose Biosciences stock. Sigma Planning Corp lifted its holdings in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 401,750 shares of the biotechnology company’s stock after acquiring an additional 167,282 shares during the quarter. Sigma Planning Corp owned approximately 2.22% of Aptose Biosciences worth $165,000 at the end of the most recent reporting period. Institutional investors own 26.62% of the company’s stock.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.